Abstract
A 26-kDa trypsin inhibitor with an N-terminal sequence resembling storage proteins was purified from moth beans (Phaseolus acutifolius). It dose-dependently inhibited trypsin with an IC50 value of about 0.38 μM. It inhibited [methyl-3H] thymidine incorporation by lymphoma MBL2 cells with an IC50 value of 20 μM.
Keywords: antiproliferative, lymphoma cells, moth bean, purification, storage protein, trypsin inhibitor
Protein & Peptide Letters
Title: A Storage Protein-Like Trypsin Inhibitor from the Moth Bean (Phaseolus acutifolius) with Antiproliferative Activity Toward Lymphoma Cells
Volume: 17 Issue: 6
Author(s): D.Z. Ma, J. Sun, G.Q. Zhang, H.X. Wang and T.B. Ng
Affiliation:
Keywords: antiproliferative, lymphoma cells, moth bean, purification, storage protein, trypsin inhibitor
Abstract: A 26-kDa trypsin inhibitor with an N-terminal sequence resembling storage proteins was purified from moth beans (Phaseolus acutifolius). It dose-dependently inhibited trypsin with an IC50 value of about 0.38 μM. It inhibited [methyl-3H] thymidine incorporation by lymphoma MBL2 cells with an IC50 value of 20 μM.
Export Options
About this article
Cite this article as:
Ma D.Z., Sun J., Zhang G.Q., Wang H.X. and Ng T.B., A Storage Protein-Like Trypsin Inhibitor from the Moth Bean (Phaseolus acutifolius) with Antiproliferative Activity Toward Lymphoma Cells, Protein & Peptide Letters 2010; 17 (6) . https://dx.doi.org/10.2174/092986610791190408
DOI https://dx.doi.org/10.2174/092986610791190408 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review
Current Cancer Drug Targets Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry New Benzothiazole/thiazole-Containing Hydroxamic Acids as Potent Histone Deacetylase Inhibitors and Antitumor Agents
Medicinal Chemistry In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity
Current Drug Metabolism Neuregulin Signaling in Pieces-Evolution of the Gene Family
Current Pharmaceutical Design Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry IL-15 and HIV Infection: Lessons for Immunotherapy and Vaccination
Current HIV Research A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets A Review on Application of Particle Swarm Optimization in Bioinformatics
Current Bioinformatics Curcumin Against Malaria: From Traditional Medicine to Development of Synthetic Analogs; A Bioorganic Approach
Current Traditional Medicine NBS1 Heterozygosity and Cancer Risk
Current Genomics Gauging Reactive Metabolites in Drug-Induced Toxicity
Current Medicinal Chemistry Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML
Current Pharmaceutical Biotechnology Rho GTPases: Promising Cellular Targets for Novel Anticancer Drugs
Current Cancer Drug Targets <i>In Silico</i> Docking Studies of Vascular Endothelial Growth Factor-A (VEGFA): Possible Implications in Chronic Myeloid Leukemia (CML) Therapy
Current Proteomics Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry